In an unrated note published in a question and answer format on Dec 14, PhillipCapital’s research team spoke to Biolidics on the company’s recent developments on its SARS-CoV-2 Antigen Rapid Test Kit and other Covid-19 test kits.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply